(3-benzo[1,3]dioxol-5-yl-3-tetrazol-2-yl-propyl)-dimethyl-amine | 1198349-24-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: (3-benzo[1,3]dioxol-5-yl-3-tetrazol-2-yl-propyl)-dimethyl-amine
• 英文别名: 3-(1,3-benzodioxol-5-yl)-N,N-dimethyl-3-(tetrazol-2-yl)propan-1-amine
• CAS: 1198349-24-4
• 化学式: C₁₃H₁₇N₅O₂
• 分子量: 275.31
• InChiKey: JPRJFHZXVUKROD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  65.3
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• 3-Substituted Propanamine Compounds
  申请人：Park Chun-Eung

  公开号：US20100311789A1

  公开（公告）日：2010-12-09

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本发明涉及由以下结构式(I)表示的混合或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本发明还涉及含有该化合物的制药组合物。所述化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍，具有有用性。
• 3-SUBSTITUTED PROPANAMINE COMPOUNDS
  申请人：Park Chun-Eung

  公开号：US20120046312A1

  公开（公告）日：2012-02-23

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

  本文披露了由以下结构式（I）表示的外消旋或对映富集的3-取代丙胺化合物或其药学上可接受的盐。本文还披露了含有该化合物的药物组合物。该化合物对于治疗中枢神经系统疾病，如抑郁症、焦虑症和疼痛障碍非常有用。
• US8101642B2
  申请人：——

  公开号：US8101642B2

  公开（公告）日：2012-01-24
• US8404730B2
  申请人：——

  公开号：US8404730B2

  公开（公告）日：2013-03-26
• [EN] 3-SUBSTITUTED PROPANAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE PROPANAMINE À SUBSTITUTION 3
  申请人：SK HOLDINGS CO LTD

  公开号：WO2009148290A2

  公开（公告）日：2009-12-10

  Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I) or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.